Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hologic, Inc. (Nasdaq: HOLX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware corporation with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC, Hologic submits periodic and current reports that offer detailed insight into its operations, financial performance and material corporate events.
Among the most closely watched documents for Hologic are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s diagnostics, breast health, GYN surgical and skeletal health businesses, outline risk factors and discuss segment performance. Current reports on Form 8-K provide timely updates on specific events, such as quarterly earnings releases, changes to executive compensation arrangements and material transactions.
Recent 8-K filings have included the announcement of financial results for the fourth quarter of fiscal 2025, along with reconciliations of non-GAAP measures such as adjusted EBITDA and non-GAAP EPS, and the disclosure of a revised form of restricted stock unit award agreement approved by the Compensation Committee. Another 8-K details the Agreement and Plan of Merger under which a merger subsidiary affiliated with funds managed by Blackstone and TPG will merge with and into Hologic, with Hologic surviving as a wholly owned subsidiary of a parent entity. That filing also notes that, if the merger is consummated, Hologic’s common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
On this page, users can review Hologic’s 8-K filings related to transaction announcements, executive employment agreement amendments and results of operations, alongside its periodic reports when available. These filings help investors understand how Hologic’s diagnostics, breast health, GYN surgical and skeletal health segments contribute to overall results, how non-GAAP metrics are defined, and how material agreements—such as the proposed merger with Blackstone- and TPG-affiliated entities—may affect the company’s capital structure and listing status.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain key points in plain language. This can be especially helpful for lengthy filings like 10-K and 10-Q reports, as well as complex transaction-related 8-Ks. Users interested in HOLX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures and track how Hologic’s regulatory reporting reflects developments in its medical technology and women’s health businesses.
Hologic, Inc. reported results from a special shareholder meeting held to vote on its proposed acquisition by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC. Shareholders approved the Merger Agreement, with 178,777,739 votes for, 151,271 against and 117,121 abstaining.
On the record date, 223,065,562 shares were entitled to vote, and 179,046,131 shares, or about 80.27% of voting power, were present, establishing a quorum. An advisory, non‑binding proposal on potential executive compensation related to the merger was not approved, with 60,764,502 votes for and 115,723,408 against.
Because the merger proposal passed, no adjournment vote was needed. The merger is expected to close in March or April 2026, subject to required regulatory approvals and other customary closing conditions.
Hologic, Inc. insider filing amendment: SVP of Human Resources Ms. De Walt reported that 4,416 shares of Hologic common stock were withheld on 01/30/2026 to satisfy tax obligations tied to vested restricted stock units at a price of $74.93 per share. After this tax withholding, she directly beneficially owned 7,603 Hologic shares.
This document is an amendment to a prior Form 4 and was filed solely to attach the correct Power of Attorney. The underlying transactions and share amounts remain unchanged from the original report.
Hologic, Inc. senior vice president Diana De Walt reported a routine tax‑withholding transaction in company stock. On January 30, 2026, 4,416 shares of Hologic common stock were withheld at $74.93 per share to cover tax obligations from vested restricted stock units.
After this Form 4 transaction, De Walt directly beneficially owned 7,603 shares of Hologic common stock. The filing describes no open‑market purchase or sale; the shares were retained by the company solely to satisfy tax withholding tied to equity compensation.
Hologic reported modest revenue growth but lower profit while preparing to go private in a major buyout. Quarterly revenue rose to $1,047.8 million from $1,021.8 million, driven by higher GYN Surgical and Skeletal Health sales. Net income declined to $179.1 million from $201.0 million, with diluted EPS down to $0.79 from $0.87.
Diagnostics revenue was essentially flat as lower COVID and certain STI testing offset growth in vaginitis and open-access assays. Breast Health dipped, including a recall-driven halt of Brevera 9 Gauge needles, while GYN Surgical benefited from the $340.7 million Gynesonics acquisition. Cash and cash equivalents increased to $2,168.0 million.
Hologic also agreed to be acquired by funds managed by Blackstone and TPG for $76.00 per share in cash plus a non-tradable contingent value right of up to $3.00 per share, tied to Breast Health revenue targets in fiscal 2026–2027. The deal is expected to close in the first half of 2026, after shareholder and regulatory approvals, and would result in Hologic’s Nasdaq delisting. A major BioZorb product-liability case was settled with the amount fully covered by insurance.
Hologic, Inc. furnished an 8-K to provide a press release announcing its financial results for the first quarter ended December 27, 2025. The press release is included as Exhibit 99.1, and the company specifies that this information is furnished, not filed, under securities laws.
The filing also highlights that Hologic has a pending proposed acquisition by affiliates of Blackstone Inc. and TPG Capital, and notes that a Definitive Proxy Statement was filed on December 23, 2025 and mailed to stockholders. Hologic directs stockholders to SEC and company investor relations websites for free copies of the proxy materials and explains that its directors and executive officers may be deemed participants in the proxy solicitation.
Hologic filed an update tied to its pending sale to affiliates of Blackstone and TPG, adding merger‑related disclosures, product updates and litigation developments. The company describes stockholder lawsuits and demand letters claiming the merger proxy omitted material information and responds by supplementing valuation details from Goldman Sachs, including discounted cash flow work that implied a per‑share value range of $66.67 to $99.09 and takeover premium analyses based on prior large U.S. deals.
Hologic also reports a voluntary recall and ongoing stop‑ship for its Brevera 9 Gauge Needles, which represented about 4.7% of Breast Health revenue in fiscal 2025. Because the duration and mitigation efforts are uncertain, Hologic now believes the risk‑adjusted net present value of each contingent value right is likely below the earlier $2.54 estimate, making the 2026 CVR milestone harder to reach despite a possible 2027 “catch‑up” feature. Separately, the company has reached a settlement, fully covered by insurance, to resolve most BioZorb product liability cases with no expected financial liability.
Hologic, Inc. filed an amended annual report to add detailed Part III disclosures on directors, executive officers, governance and 2025 executive pay. The filing explains a performance‑heavy compensation program built around base salary, annual cash bonuses tied to adjusted revenue and adjusted EPS, and long‑term equity awards split among performance stock units, restricted stock units and stock options.
For fiscal 2025, short‑term incentives paid out at 76% of target based on adjusted revenue of $4.063 billion and adjusted EPS of $4.33. Performance stock units based on adjusted free cash flow, adjusted return on invested capital and relative total shareholder return vested between 100% and 200% of target, reflecting three‑year performance. The filing also details how outstanding equity awards and new cash retention bonuses for several named executives will be treated in connection with a pending merger at $76.00–$79.00 per share, including accelerated vesting, cash payments and contingent value rights.
Hologic executive President, GYN Surgical reported a routine tax-related stock transaction. On December 12, 2025, 90 shares of Hologic common stock were disposed of at $75 per share as shares were withheld to satisfy tax obligations tied to vested restricted stock units. Following this withholding, the officer directly beneficially owns 17,512 Hologic shares.
Hologic, Inc. insider equity update: The Chairman, President and CEO, who is also a director of Hologic, Inc. (HOLX), reported a routine equity transaction dated 11/14/2025. A total of 6,874 shares of common stock were withheld at a price of $74.15 per share to cover tax obligations arising from the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the reporting person beneficially owns 1,423,837 shares of Hologic common stock directly and 1,146,829 shares indirectly through the MacMillan Family Trust. The indirect holdings include 1,079,673 restricted stock units/performance stock units for which settlement has been deferred under the company’s Deferred Equity Plan.
Hologic Inc. executive reports small tax-related share withholding
Hologic Inc. Group President, International reported a routine equity transaction involving the company’s common stock. On 11/14/2025, 196 shares of Hologic common stock were withheld at a price of $74.15 per share to cover tax obligations tied to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. Following this withholding transaction, the executive directly beneficially owns 134,039 shares of Hologic common stock.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
